Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology. 2016; 64: 73-84
- Prospective study of outcomes in adults with nonalcoholic fatty liver disease.N Engl J Med. 2021; 385: 1559-1569
- Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.Gastroenterology. 2020; 158: 1611-1625 e12
- Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology. 2015; 149: 389-397 e10
- Association of histologic disease activity with progression of nonalcoholic fatty liver disease.JAMA Netw Open. 2019; 2: e1912565
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.Hepatology. 2013; 57: 1357-1365
- Impact of non-invasive biomarkers on hepatology practice: past, present and future.J Hepatol. 2022; 76: 1362-1378
- Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease.Gastroenterology. 2019; 156: 1264-1281 e4
- Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol. 2019; 17: 156-163 e2
- Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.JHEP Rep. 2021; 3: 100381
- Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.J Hepatol. 2017; 66: 1022-1030
- Prospective, same-day, direct comparison of controlled attenuation parameter with the M vs the XL probe in patients with nonalcoholic fatty liver disease, using magnetic resonance imaging-proton density fat fraction as the standard.Clin Gastroenterol Hepatol. 2020; 18: 1842-1850 e6
- Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.Lancet Gastroenterol Hepatol. 2021; 6: 185-198
- Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.Hepatology. 2018; 67: 1348-1359
- Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.Gastroenterology. 2019; 156: 1717-1730
- Electronic address eee, Clinical practice guideline P, Chair, et al. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.J Hepatol. 2021; 75: 659-689
- Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis.Eur Radiol. 2019; 29: 3564-3573
- Accuracy of liver fat quantification with advanced CT, MRI, and ultrasound techniques: prospective comparison with MR spectroscopy.AJR Am J Roentgenol. 2017; 208: 92-100
- Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Hepatology. 2016; 64: 2234-2243
- Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial.Hepatology. 2012; 56: 922-932
- Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib.J Hepatol. 2019; 70: 133-141
- Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH.Hepatology. 2020; 72: 1219-1229
- Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis.Gastroenterology. 2017; 153: 753-761
- Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis.Clin Gastroenterol Hepatol. 2021; 19: 2274-2283 e5
- Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults.Abdom Imaging. 2015; 40: 3070-3077
- Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.Hepatology. 2013; 58: 1930-1940
- Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis.J Hepatol. 2021; 75: 770-785
- Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants.Clin Gastroenterol Hepatol. 2019; 17: 630-637 e8
- Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.Gut. 2022; 71: 1006-1019
- Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials.Hepatology. 2019; 70: 1521-1530
- FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.Lancet Gastroenterol Hepatol. 2020; 5: 362-373
- Validation of the accuracy of the FAST score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.PLoS One. 2022; 17: e0266859
- Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: comparison between M and XL probes.Hepatol Res. 2020; 50: 831-839
- Validation of the FibroScan-aspartate aminotransferase score by vibration-controlled transient and B-mode ultrasound elastography.Hepatol Res. 2021; 51: 652-661
- Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study.Hepatology. 2014; 60: 1920-1928
- Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease.Gastroenterology. 2017; 152: 598-607 e2
- Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography.Gastroenterology. 2016; 150: 626-637 e7
- MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.Gut. 2021; 70: 1946-1953
- Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.Hepatology. 2022; 75: 661-672
- Head to head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.J Hepatol. 2022; 77: 1482-1490
- MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.J Hepatol. 2022; 76: 781-787
- Noninvasive algorithms for the case finding of “at-risk” patients with NAFLD.Semin Liver Dis. 2022; 42: 313-326
- Embedding assessment of liver fibrosis into routine diabetic review in primary care.JHEP Rep. 2021; 3: 100293
- Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.J Hepatol. 2022; 76: 1013-1020
- Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States health care system.Clin Gastroenterol Hepatol. 2020; 18: 2305-2314 e12
- American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the american association for the study of liver diseases (AASLD).Endocr Pract. 2022; 28: 528-562
Article info
Publication history
Published online: March 09, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
